Trial intelligence / Profile preview

Anamnestic Immune Response After HBVAXPRO Primary Series

NCT00393523Phase 3Completed

Sponsor
Merck & Co.
Start
Sep 2006
Primary completion
Jun 2008
Modality
Split/Subunit Vaccines, Recombinant Protein Vaccines
01

Overview

A Phase 3 trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by Merck & Co.. Started Sep 2006; status: completed.

02

Drugs

Hepatitis B vaccine
03

Conditions

hepatitis B (HBV)

Beyond the preview

Go deeper on NCT00393523.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00393523.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call